[go: up one dir, main page]

IN2012DN02423A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02423A
IN2012DN02423A IN2423DEN2012A IN2012DN02423A IN 2012DN02423 A IN2012DN02423 A IN 2012DN02423A IN 2423DEN2012 A IN2423DEN2012 A IN 2423DEN2012A IN 2012DN02423 A IN2012DN02423 A IN 2012DN02423A
Authority
IN
India
Prior art keywords
mif
cxcr2
cxcr4
homomultimer
inhibits
Prior art date
Application number
Inventor
Jurgen Bernhagen
Christian Weber
Benedikt Vollrath
Court Turner
Joshua Robert Schultz
Alma Zernecke
Sergio Duron
Original Assignee
Carolus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carolus Therapeutics Inc filed Critical Carolus Therapeutics Inc
Publication of IN2012DN02423A publication Critical patent/IN2012DN02423A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein, in some embodiments, are methods for treating an MIF-mediated disorder. In some embodiments, the method comprises administering an agent that inhibits (i) MIF binding to CXCR2 and CXCR4 and/or (ii) MIF- activation of CXCR2 and CXCR4; (iii) the ability of MIF to form a homomultimer; or a combination thereof.
IN2423DEN2012 2009-09-23 2010-09-23 IN2012DN02423A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24521409P 2009-09-23 2009-09-23
US31903910P 2010-03-30 2010-03-30
PCT/US2010/050047 WO2011038149A2 (en) 2009-09-23 2010-09-23 Methods of treating inflammation

Publications (1)

Publication Number Publication Date
IN2012DN02423A true IN2012DN02423A (en) 2015-08-21

Family

ID=43796491

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2423DEN2012 IN2012DN02423A (en) 2009-09-23 2010-09-23

Country Status (9)

Country Link
EP (1) EP2480579A4 (en)
KR (1) KR20120105429A (en)
CN (1) CN102725311A (en)
AU (1) AU2010298249A1 (en)
BR (1) BR112012006468A2 (en)
CA (1) CA2773978A1 (en)
IN (1) IN2012DN02423A (en)
MX (1) MX2012003514A (en)
WO (1) WO2011038149A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2731970B1 (en) 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
NZ702315A (en) * 2012-05-17 2016-10-28 Cyon Therapeutics Inc Methods and uses for pro protein convertase subtilisin kexin 9 (pcsk9) inhibitors
AR098418A1 (en) * 2013-11-14 2016-05-26 Baxter Healthcare Sa INHIBITORY FACTOR OF IMMIGRATION OF MACROPHAGUS (MIF) AS THERAPEUTIC OBJECTIVE
BR112018068393A2 (en) 2016-03-11 2019-01-15 Ardea Biosciences Inc cxcr-2 inhibitors for the treatment of crystal arthropathy disorders
US11679146B2 (en) 2018-06-05 2023-06-20 Anji Pharmaceuticals Inc. Compositions and methods for treating pancreatitis
EP3884277A1 (en) * 2018-12-26 2021-09-29 Colgate-Palmolive Company Biomarkers of neutrophil deregulation as diagnostic for gingivitis
MX2022011231A (en) * 2020-03-11 2022-11-07 Biolinerx Ltd CXCR4 INHIBITOR FOR THE TREATMENT OF ACUTE RESPIRATORY DIFFICULTY SYNDROME AND VIRAL INFECTIONS.
WO2021219495A1 (en) * 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication
CN112656934A (en) * 2021-01-22 2021-04-16 深圳市图微安创科技开发有限公司 Application of polypeptide AT03 in medicine for treating primary biliary cholangitis
EP4378319A1 (en) * 2022-12-01 2024-06-05 Bioiberica, S.A.U. Composition comprising bioactive peptides
CN119318647A (en) * 2024-08-14 2025-01-17 南方医科大学 Application of SB225002 in preparation of medicine for treating myocardial infarction and composition for treating myocardial infarction

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US20040009149A1 (en) * 2002-02-27 2004-01-15 Altman John D. Multimeric binding complexes
JP4472351B2 (en) * 2002-03-01 2010-06-02 イミューノメディクス、インコーポレイテッド Internalizing anti-CD74 antibody and method of use thereof
WO2005065328A2 (en) * 2003-12-30 2005-07-21 The United States Of America, As Represented By The Department Of Veterans Affairs Macrophage migration inhibitory factor (mif) as marker for urological inflammatory disease
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2009117706A2 (en) * 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treatment using anti-mif antibodies
US20100183598A1 (en) * 2008-11-12 2010-07-22 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders

Also Published As

Publication number Publication date
AU2010298249A1 (en) 2012-04-19
MX2012003514A (en) 2012-04-19
CA2773978A1 (en) 2011-03-31
EP2480579A4 (en) 2013-07-31
KR20120105429A (en) 2012-09-25
BR112012006468A2 (en) 2016-08-09
WO2011038149A2 (en) 2011-03-31
CN102725311A (en) 2012-10-10
WO2011038149A3 (en) 2011-10-27
EP2480579A2 (en) 2012-08-01

Similar Documents

Publication Publication Date Title
IN2012DN02423A (en)
WO2009117710A3 (en) Methods of treating inflammation
MX2010006823A (en) Methods for the treatment of gout.
AU2008232453A8 (en) Methods and compositions for reduction of side effects of therapeutic treatments
MX2010009724A (en) Methods of treating inflammatory pain.
MX2018013333A (en) Therapeutic nuclease compositions and methods.
MY191313A (en) Use of chimeric antigen receptor-modified t cells to treat cancer
EP3489360A3 (en) Modulation of nuclear-retained rna
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
TW200738262A (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
WO2009080800A3 (en) Method for decreasing abdominal girth by administering a bifidobacterium bacteria
MX2011006725A (en) Combination of aurora kinase inhibitors and anti-cd20 antibodies.
WO2009016488A3 (en) Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods
SG179069A1 (en) Cancer stem cell-targeted and drug resistant cancer therapy
EP2566502A4 (en) Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
MX2011012538A (en) Combination therapy for the treatment of multiple myeloma.
AU2010298020A8 (en) Combination
WO2008073317A3 (en) Cytarabine for treatment of glioma
TN2011000206A1 (en) Compositions and methods of use soluble thrombomodulin variants
PH12012500873A1 (en) Multilayer pharmaceutical composition that can be dispersed in water and which contains a combination of antimalarial agents
UA41936U (en) Method for treating kraurosis of vulva in children
UA83743C2 (en) Method for prevention and correction of diminished central nervous system functional ability
UA54014U (en) Method for treating chronic non-calculous cholecystitis combined with obesity
TN2010000463A1 (en) Compositions and methods for preparing and using same
UA27829U (en) Method for treating prosthetic stomatitis against the background of metabolic syndrome